Concise Review: The High Cost of High Tech Medicine: Planning Ahead for Market Access
Abstract Cellular therapies and other regenerative medicines are emerging as potentially transformative additions to modern medicine, but likely at a staggering financial cost. Public health care systems’ budgets are already strained by growing and aging populations, and many private insurer's...
Main Authors: | Dawn Driscoll, Stephanie Farnia, Panos Kefalas, Richard T. Maziarz |
---|---|
Format: | Article |
Language: | English |
Published: |
Oxford University Press
2017-08-01
|
Series: | Stem Cells Translational Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/sctm.16-0487 |
Similar Items
-
First Complete Remission versus other- than- First Complete Remission in Acute Myelogenous Leukemia with Allogeneic Hematopoietic Stem Cell Transplantation
by: Ardeshir Ghavamzadeh, et al.
Published: (2009-04-01) -
First Complete Remission versus other- than- First Complete Remission in Acute Myelogenous Leukemia with Allogeneic Hematopoietic Stem Cell Transplantation
by: Ardeshir Ghavamzadeh, et al.
Published: (2009-06-01) -
History and Development of Autologous Stem Cell Transplantation for Acute Myeloid Leukemia
by: Norbert Claude Gorin
Published: (2021-07-01) -
Autologous hematopoietic stem cell transplantation as late high-dose consolidation in adult patients with T-cell lymphoblastic leukemias: Results of a Russian multicenter study
by: E N Parovichnikova, et al.
Published: (2015-07-01) -
THE EFFICACY OF HIGH-DOSE CONSOLIDATION AND AUTOLOGOUS BONE MARROW TRANSPLANTATION IN FIRST REMISSION OF ACUTE MYELOID LEUKEMIA
by: I. A. Samorodova, et al.
Published: (2018-05-01)